enewschannels.com — Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G’s anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer.